back to Newsletters
Happy New Year! We hope you had a terrific holiday season and that your 2014 is off to a great start!

In this January issue:

Upcoming Alumni Association Events
Policy Changes that Affect You

Upcoming Alumni Association Events 

GLOBAL FELLOWSHIP RECEPTION | MONDAY, JANUARY 13
5-7pm | Clark Center, Room E100
Help Biodesign welcome the incoming India and Singapore fellows! Please RSVP by January 9th.
Event Details & Sign Up
TABLESIDE CHAT WITH LOMA VISTA MEDICAL | TUESDAY, JANUARY 14
6:15pm | Caffe Riace, Palo Alto
Please join us as we host Stanford Alumni Alex Tilson, founder and CEO, and Mark Scheeff, VP of R&D, for the first event in this year's great Tableside Chat series. Loma Vista Medical was a dynamic, innovative TAVR balloon start-up recently acquired by CR Bard in July of 2013. Alex and Mark will share their experiences and lessons learned in bringing a novel technology from concept to acquisition in a lean start-up environment. Registration for this event will close on January 10th.
Event Details & Sign Up                         

Policy Changes that Affect You

OBAMACARE BEGINS       January 1st marked Day 1 of Obamacare. An estimated 2.1 million people are currently enrolled, below the administration's original target of 3 million. After a botched website rollout and a surprise change in plans for millions of current enrollees, problems continue to plague the landmark program. How exactly Obamacare will transform America's healthcare landscape is yet to be seen, but one thing is for sure -- the medtech industry will need to adapt to keep up with these changes. Read More.

CDRH LAUNCHES VOLUNTARY COMPLIANCE IMPROVEMENT PROGRAM
CDRH has announced an ongoing initiative to promote medical device quality called the Voluntary Compliance Improvement Program (VCIP) pilot. This is a program where manufacturers work with third-party expert consultants to analyze potential deficiencies in their quality system and improve them, while temporarily exempting them from routine FDA inspections and audits. Read More.

January 2014

9

back to Newsletters

Happy New Year! We hope you had a terrific holiday season and that your 2014 is off to a great start!
In this January issue:
  • Upcoming Alumni Association Events
  • Policy Changes that Affect You

Upcoming Alumni Association Events 

GLOBAL FELLOWSHIP RECEPTION | MONDAY, JANUARY 13

5-7pm | Clark Center, Room E100
Help Biodesign welcome the incoming India and Singapore fellows! Please RSVP by January 9th.
Event Details & Sign Up

TABLESIDE CHAT WITH LOMA VISTA MEDICAL | TUESDAY, JANUARY 14

6:15pm | Caffe Riace, Palo Alto

Please join us as we host Stanford Alumni Alex Tilson, founder and CEO, and Mark Scheeff, VP of R&D, for the first event in this year’s great Tableside Chat series. Loma Vista Medical was a dynamic, innovative TAVR balloon start-up recently acquired by CR Bard in July of 2013. Alex and Mark will share their experiences and lessons learned in bringing a novel technology from concept to acquisition in a lean start-up environment. Registration for this event will close on January 10th.

Event Details & Sign Up                         

Policy Changes that Affect You

OBAMACARE BEGINS       January 1st marked Day 1 of Obamacare. An estimated 2.1 million people are currently enrolled, below the administration’s original target of 3 million. After a botched website rollout and a surprise change in plans for millions of current enrollees, problems continue to plague the landmark program. How exactly Obamacare will transform America’s healthcare landscape is yet to be seen, but one thing is for sure — the medtech industry will need to adapt to keep up with these changes. Read More.

CDRH LAUNCHES VOLUNTARY COMPLIANCE IMPROVEMENT PROGRAM

CDRH has announced an ongoing initiative to promote medical device quality called the Voluntary Compliance Improvement Program (VCIP) pilot. This is a program where manufacturers work with third-party expert consultants to analyze potential deficiencies in their quality system and improve them, while temporarily exempting them from routine FDA inspections and audits. Read More.